10x Genomics, Inc. reaffirmed revenue guidance for the year 2024. The company maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.52 USD | -2.31% | -7.99% | -57.93% |
May. 15 | Transcript : 10x Genomics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM | |
May. 07 | Bruker's NanoString Secures Patent Case Win in Germany | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.93% | 2.88B | |
-5.86% | 12.09B | |
-3.26% | 8.21B | |
+5.47% | 5.74B | |
+29.66% | 5.64B | |
-9.05% | 4.16B | |
+11.87% | 2.69B | |
-5.19% | 2.33B | |
+23.62% | 2.17B | |
-4.87% | 1.86B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- 10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024